Dear Editor,

Infected aortic aneurysm (IAA) is an uncommon, but life-threatening condition. Identification of the causative pathogen is essential for accurate diagnosis and effective treatment. However, 14--40% of IAA cases are culture-negative \[[@B1]\]. IAA due to *Streptococcus pneumoniae* is rare, and reports of the involvement of *S. pneumoniae* capsular serotypes and sequence types (STs) in IAA are even rarer \[[@B2][@B3][@B4][@B5]\]. We identified *S. pneumoniae* from culture-negative IAA by genetic analysis. To the best of our knowledge, as of 2019, only 59 cases of pneumococcal IAA have been reported in France, the United Kingdom (UK), the Netherlands, Germany, Switzerland, Belgium, Denmark, the United States (USA), Canada, Chile, Japan, Hong Kong, Korea, and Austria since 1977 \[[@B2][@B3][@B4][@B5]\]. In the previous cases of IAA due to *S. pneumoniae*, capsular serotype analysis was reported only for seven: 10A and 23F in the UK, 4 and 8 in Denmark, 19F in Hong Kong, 4 in Belgium, and 23 in USA \[[@B2][@B3][@B4][@B5]\]. We report the first two cases of culture-negative IAA due to non-vaccine *S. pneumoniae* serotype 23A, ST338. The study protocol was approved by the Institutional Ethics Committees of Tohoku University, Sendai, Japan (No. 2018-1-456).

Case 1 was of a 68-year-old female treated in 2017 for three aneurysms in the thoracic aorta. Case 2 was of a 70-year-old male treated in 2014 for a ruptured pararenal aortic aneurysm. Informed consent was obtained from the patient in case 1, and in case 2, research information has been disclosed in accordance with the ethical guidelines for Medical and Health Research Involving Human Subjects established by the Japanese Ministry of Health, Labor and Welfare (<https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/hokabunya/kenkyujigyou/i-kenkyu/index.html>). Both patients had no history of disease-causing immune deficiency or pneumococcal vaccination and underwent surgical treatment. In case 1, the two larger aneurysms were resected during staged surgeries. In case 2, the aneurysm ruptured, leading to abscess formation in the anterior cavity of the iliopsoas muscle, and left renal artery was reconstructed owing to occlusion.

As the blood and tissue cultures were negative in both cases, 16S ribosomal RNA gene analysis of tissue was performed as described previously \[[@B1]\]. In both cases, the sequence similarity was the highest with *S. pneumoniae*, and species identification was further confirmed by amplification of the *lytA* region, which is specific to *S. pneumoniae* \[[@B6]\]. In case 1, *S. pneumoniae* was identified in two separate aneurysms. Oral antibiotics were prescribed for both patients at discharge, and no recurrence has been reported.

The serotype of the *S. pneumoniae* isolated from each patient was identified as 23A following the US Centers for Disease Control and Prevention protocols for conventional PCR (<https://www.cdc.gov/streplab/pneumococcus/resources.html>) \[[@B7]\]. Multilocus sequence typing (MLST) analysis was performed according to the *S. pneumoniae* MLST Database (<https://pubmlst.org/spneumoniae/>); in both cases, *S. pneumoniae* was identified as ST338, clonal complex 156. Alterations in *pbp2x* and *pbp2b*, genes encoding penicillin-binding protein that mediate β-lactam resistance in *S. pneumoniae*, were identified in both cases \[[@B8]\]. Mutations in the quinolone resistance-determining region of *gyrA* and *parC*, which are important determinants of levofloxacin resistance \[[@B9]\], were not detected in either case. The clinical and molecular characteristics of both cases are detailed in [Table 1](#T1){ref-type="table"}.

In Japan, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced for children younger than five yrs in 2010 and was replaced with PCV13 in 2013. In 2014, the 23-valent pneumococcal polysaccharide vaccine was introduced for vaccination in adults over 65 years. Depending on the effect of vaccination, reduced carriage and incidence of invasive pneumococcal disease (IPD) and increased prevalence of non-vaccine serotypes (NVTs) in IPD cases have been reported \[[@B10]\]. According to recent Japanese surveillance studies, the proportion of IPD cases attributed to serotype 23A (an NVT) has been increasing since the introduction of PCVs \[[@B10]\]. More than 90% of 23A isolates from adult IPD cases showed alterations in *pbp2x* and *pbp2b*, and approximately a half of them were reported as ST338, similar to the isolates in the current cases. Genetic analysis of the isolates in our cases indicated susceptible to levofloxacin, as reported in previous IPD cases in Japan \[[@B10]\]. Although the current cases were successfully treated, the isolates were NVTs and harbored *pbp2x* alterations, making them resistant to cephems. As cephem antibiotics are used frequently in Japan, there is a concern that antibiotic selection pressure will lead to an increase in the proportion of drug-resistant isolates. Moreover, with the introduction of PCVs, there is also a concern regarding the relative increase in NVTs and drug-resistant isolates.

In conclusion, we identified 23A *S. pneumoniae*, ST338, in culture-negative IAA for the first time in two independent cases, raising the concern that NVT and drug-resistant pneumococci may exist in culture-negative IAA cases. Further epidemiological studies and investigation of preventive measures for IPD, including IAA, are required.
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###### Clinical and molecular characteristics of two cases with *Streptococcus pneumoniae*-infected aortic aneurysms
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  Variables                                                   Case 1                                                         Case 2
  ----------------------------------------------------------- -------------------------------------------------------------- --------------------------------------------------------------------------------------------------
  Age (yr), Sex                                               68, Female                                                     70, Male
  Underlying diseases                                         Sigmoid colon cancer (postoperative), hypertension             Bronchial asthma, hypertension, hyperuricemia, hyperlipidemia
  Risk factors for infection                                  None                                                           None
  Pneumococcal vaccination history                            None                                                           None
  Clinical presentation                                       Fever, back pain                                               Fever, lumbar pain
  Site of aneurysm (size in mm; by CT)                        Ascending aorta (58), descending aorta (34, \< 30)             Pararenal (40)
  Inflammation around aneurysm (CT)                           Positive (observed in the two larger aneurysms)                Positive
  Maximum temperature before surgery (℃)                      37.5                                                           38.4
  Maximum white blood cell count (× 10^9^/L) before surgery   8.4                                                            15.5
  Maximum C-reactive protein (nmol/L) before surgery          1,104.8                                                        1,695.3
  Surgical management                                         *In situ* grafting                                             *In situ* grafting
  Microbiological diagnosis                                                                                                  
   Blood culture                                              Negative                                                       Negative
   Tissue culture                                             Negative                                                       Negative
   16S rRNA gene sequence similarity^\*^                      99.64%                                                         99.86%
   *lytA* (specific to *S. pneumoniae*)                       Positive                                                       Positive
   Serotype                                                   23A                                                            23A
   MLST                                                       ST338 (CC 156)                                                 ST338 (CC 156)
   Alterations in PBP genes                                   Positive (*pbp2x* and *pbp2b*)                                 Positive (*pbp2x* and *pbp2b*)
   Amino acid substitutions in QRDR (GyrA and ParC)           None                                                           None
  Anti-microbial therapy                                                                                                     
   Before admission                                           None                                                           Ceftriaxone
   After admission                                            Vancomycin (0.75→2.5 g/day^†^) and gentamicin (150 mg/day)     Piperacillin-tazobactam (9 g/day) and vancomycin (1 g/day), then teicoplanin (400→200 mg/day^‡^)
   After identification of the pathogen                       Sulbactam-ampicillin (6 g/day) and levofloxacin (500 mg/day)   Sulbactam-ampicillin (9 g/day)
   At discharge                                               Oral amoxicillin (750 mg/day) and levofloxacin (500 mg/day)    Oral amoxicillin (1,500 mg/day)
  Hospital treatment period (days)                            60                                                             61
  Postoperative complications                                 None                                                           Mild decline in renal function
  Outcome                                                     Alive                                                          Alive

^\*^Compared with *S. pneumoniae* type strains NCTC 7465^T^ (case 1) and ATCC 33400^T^ (case 2); ^†^Vancomycin started at 0.75 g/day and increased to 2.5 g/day; ^‡^Teicoplanin started at 400 mg/day and decreased to 200 mg/day.

Abbreviations: rRNA, ribosomal RNA; CC, clonal complex; CT, computed tomography; MLST, multilocus sequence typing; QRDR, quinolone resistance-determining region; ST, sequence type; PBP, penicillin binding protein; NCTC, National Collection of Type Cultures; ATCC, American Type Culture Collection.
